WO2011068956A2 - Niveaux de l'analogue 3 de la follistatine (fstl3) dans le diabète gestationnel - Google Patents

Niveaux de l'analogue 3 de la follistatine (fstl3) dans le diabète gestationnel Download PDF

Info

Publication number
WO2011068956A2
WO2011068956A2 PCT/US2010/058708 US2010058708W WO2011068956A2 WO 2011068956 A2 WO2011068956 A2 WO 2011068956A2 US 2010058708 W US2010058708 W US 2010058708W WO 2011068956 A2 WO2011068956 A2 WO 2011068956A2
Authority
WO
WIPO (PCT)
Prior art keywords
fstl3
level
gdm
levels
sample
Prior art date
Application number
PCT/US2010/058708
Other languages
English (en)
Other versions
WO2011068956A3 (fr
Inventor
Ravi Thadhani
S. Ananth Karumanchi
Original Assignee
The General Hospital Corporation
Beth Israel Deaconess Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc. filed Critical The General Hospital Corporation
Publication of WO2011068956A2 publication Critical patent/WO2011068956A2/fr
Publication of WO2011068956A3 publication Critical patent/WO2011068956A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Definitions

  • This invention relates to methods of determining a pregnant subject's risk of developing glucose intolerance and/or gestational diabetes mellitus (GDM), based on levels of FSTL3, also known as Follistatin Related Gene (FLRG).
  • GDM glucose intolerance and/or gestational diabetes mellitus
  • FLRG Follistatin Related Gene
  • GDM Gestational diabetes mellitus afflicts 4% of pregnancies in the United States (Berg, C.J., et al, Obstet Gynecol, 2009. 113(5): p. 1075-81) and is associated with unfavorable perinatal outcomes including fetal macrosomia, shoulder dystocia, cesarean- section, and neonatal hypoglycemia (ACOG Practice Bulletin. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol, 2001. 98(3): p.
  • GDM is characterized by glucose intolerance, beta cell dysfunction, and insulin resistance greater than the physiologic insulin resistance of pregnancy (Kim, C, K.M.
  • GDM Global System for Mobile Communications
  • the present invention is based, at least in part, on the discovery that low FSTL3 levels, e.g., in the first trimester, are associated with the development of glucose intolerance and gestational diabetes mellitus later in pregnancy.
  • the invention features methods of determining a woman's risk of developing glucose intolerance and/or gestational diabetes during pregnancy, by obtaining a biological sample, such as blood or serum, from a pregnant woman during the first or second trimester of pregnancy (e.g., at 5 weeks after conception, or in the first trimester (6 to 12 weeks), the second trimester (13 to 27 weeks), or at 8, 10, 12, 14, 16, 18, 20, or 24 weeks after conception); and measuring the level of FSTL3 in the sample; wherein the level of FSTL3 in the sample indicates the level of risk of developing gestational diabetes.
  • the sample can be a fasting or non-fasting sample.
  • FSTL3 is detected in a urine sample (rather than or in addition to in a blood, serum, or plasma sample).
  • the methods include measuring the level of FSTL3 in a biological sample, e.g., serum, blood, or urine, obtained from the pregnant subject; measuring the level of FSTL3 in the biological sample; comparing the FSTL3 level in the sample obtained from the pregnant subject with a reference FSTL3 level.
  • the reference FSTL3 level represents a level in a subject having a normal pregnancy; a low level of FSTL3 present in the sample obtained from the pregnant subject, as compared to the levels present in the reference representing a normal pregnancy, indicates that the pregnant subject has, or is predisposed to having, GDM.
  • the reference FSTL3 level represents a threshold level, and a level in the pregnant subject that is equal to or below the reference FSTL3 level indicates an increased risk of developing GDM.
  • the reference FSTL3 level is a median level or a cutoff point for a tertile or quartile.
  • the methods further include determining risk based on additional risk factors including, but not limited to, 1) the pregnant subject's race (African American, Hispanic, or Asian subjects have a higher risk than Caucasian subjects); 2) the pregnant subject's age (increasing age means increasing risk); 3) the pregnant subject's parity (multiparity increases risk); 4) the pregnant subject's body mass index (BMI over 25 or over 29 increases risk); the presence of polycystic ovary disease (PCOD) (increases risk); family history of diabetes (increases risk); or a previous delivery of a fetus > 9 lbs (increases risk).
  • PCOD polycystic ovary disease
  • the method further includes measuring the level of FSTL3 and at least one additional biomarker in the subject biological sample, e.g., urine, blood, or serum sample, and generating a subject profile comprising a value or plurality of values, each value representing a level of FSTL3 or an additional biomarker, and comparing the subject profile with a reference profile, wherein the reference profile comprises a value or plurality of values, each value representing a level of FSTL3 or the corresponding biomarker in a reference urine sample obtained from a reference subject.
  • the additional biomarker is activin, myostatin, a specific cytokine, Sex hormone-binding globulin (SHBG), sFLTl, and/or P1GF.
  • the cytokine can be, e.g., an immune/hematopoietin, an interferon, a tumor necrosis factor (TNF)-related molecule or a chemokine.
  • TNF tumor necrosis factor
  • Examples include interleukin (IL)-6, IL-8, IL-lbeta, monocyte chemoattractant protein (MCP)-l or TNF-alpha, or any combination thereof.
  • a reference profile can be generated from a sample obtained from any source containing, or believed to contain, a cytokine. Reference levels or thresholds of activin, myostatin, SHBG, P1GF, sFLTl, cytokines and/or growth factors can be used to generate reference profiles.
  • the reference profile can be obtained from the urine, serum, plasma, or blood of a reference subject.
  • a reference subject can be a pregnant individual who has or later develops a gestational disorder or a pregnant individual having a normal pregnancy.
  • the methods of the invention can be accomplished by contacting a sample obtained from a pregnant subject with a biomolecule specific for FSTL3, e.g., an immobilized biomolecule specific for FSTL3, and detecting a modification of the biomolecule.
  • the modification is indicative of the level of FSTL3 in a sample and can include stable or transient binding of the biomolecule to FSTL3.
  • the subject FSTL3 levels can be compared to reference levels as described herein. Reference levels can further be used to generate a reference profile from one or more reference subjects.
  • the biomolecules are antibodies, such as monoclonal antibodies, or antigen-binding fragments thereof.
  • the biomolecules are receptors.
  • the invention features arrays for detecting a gestational disorder.
  • arrays include a substrate (or substrates) having a plurality of addresses, each address having disposed thereon a set of one or more biomolecules, and each biomolecule in a set specifically detecting the same molecule; wherein at least one set of one or more
  • biomolecules specifically detects FSTL3.
  • the arrays can further include biomolecules that specifically detect markers such as, for example, activin, myostatin, SHBG, soluble fms-like tyrosine kinase-1 receptor (sFlt-1), P1GF, interleukin (IL)-6, IL-8, IL-lbeta, monocyte chemoattractant protein (MCP)-l or TNF-alpha.
  • an array of the invention further includes at least two addresses having disposed thereon an immobilized biomolecule that specifically detects at least one growth factor, such as, for example, vascular endothelial growth factor (VEGF), or fibroblast growth factor (FGF)-2.
  • the array is on beads rather than a flat substrate.
  • the invention also features a pre-packaged diagnostic kit for detecting a gestational disorder.
  • the kit can include, e.g., antibodies or antigen-binding fragments thereof that bind specifically to and detect FSTL3 and optionally an additional marker, e.g., activin, myostatin, SHBG, sFlt-1, P1GF, interleukin (IL)-6, IL-8, IL-lbeta, monocyte chemoattractant protein (MCP)-l or TNF-alpha, as described herein and instructions for using the kit in a method described herein, e.g., to test a biological sample, e.g., a urine, blood, or serum sample, to determine a subject's risk of developing GDM.
  • the kit includes antibodies that detect FSTL3 and SHBG, or FSTL3 and one or both of activin and myostatin.
  • the invention also includes methods to determine the efficacy of a therapy administered to treat a gestational disorder. These methods include contacting the array with a sample obtained from a pregnant patient undergoing therapy for a gestational disorder.
  • the level of FSTL3 can be determined and compared to a level of FSTL3 detected in a sample obtained from the patient prior to, or subsequent to, the administration of the therapy.
  • a caregiver can be provided with the comparison information for further assessment.
  • An increase in FSTL3 levels would indicate a successful therapy.
  • a subject profile can be entered into a computer system that contains, or has access to, a database that includes a plurality of digitally-encoded reference profiles.
  • Each profile of the plurality has a plurality of values, each value representing a level of FSTL3 of a pregnant individual having, or predisposed to having, a gestational disorder.
  • a single subject profile can be used to identify a subject at risk for developing a gestational disorder based upon reference values.
  • the invention also features computer-readable media that contain a database including one or more digitally-encoded reference profiles, wherein a first reference profile represents a level of FSTL3 in one or more samples from one or more pregnant individuals having a gestational disorder.
  • the invention also features computer systems for determining whether a pregnant subject has, or is predisposed to having, a gestational disorder.
  • These systems include a database that has one or more digitally-encoded reference profiles, wherein a reference profile comprises a value that represents a level of FSTL3 in one or more samples from one or more pregnant individuals having a gestational disorder; and a server that includes a computer-executable code for causing the computer to: i) receive a profile of a pregnant subject comprising a level of FSTL3 detected in a sample from the subject; ii) identify from the database a matching reference profile that is diagnostically relevant to the pregnant subject profile; and iii) generate an indication of whether of the subject has, or is predisposed to having, a gestational disorder.
  • the new methods can be used as a routine screen or "pre-screen" for all pregnant women to identify those women who are not at risk for gestational complications, thus avoiding the need for additional testing later during pregnancy in those women.
  • FIG. 1 is a bar graph showing risk of developing GDM according to first trimester FSTL3 levels, by quartiles.
  • FIG. 2 is a bar graph showing the risk (odds ratio) of developing GDM based on first tertile cutpoint of ⁇ 12,000 pg/ml.
  • FIG. 3 is a box-whisker/scatter plot showing first trimester FSTL3 levels in women who did (GDM) and did not (NO GDM) develop GDM during pregnancy. FSTL3 levels were measured in serum collected from GDM and cases and controls at the first prenatal obstetric visit. FSTL3 levels were significantly lower in women who developed GDM (p ⁇ 0.001). Box plots depict the median (horizontal line in each box), the 25th percentile (bottom of each box), and the 75th percentile (top of each box). Box whiskers extend to the highest/lowest non-outlier value. Outliers were defined as lying greater than three interquartile ranges outside the 25th or 75th percentile. Scatter plot overlay depicts levels of FSTL3 in individual subjects.
  • FIG. 4 is a box plot showing the odds of developing GDM by first trimester FSTL3 tertile. Subjects were divided into tertiles based on first trimester FSTL3 level. Univariate and multivariate logistic regression analyses were used to determine odds ratios for the development of GDM in each tertile. Multivariate logistic regression model includes adjustment for age, gestational age, diastolic blood pressure, BMI, nonwhite race, and multiparity. * Significantly different from the reference tertile at the p ⁇ 0.05 level.
  • FIG. 5 is a scatter plot showing the relationship between first trimester FSTL3 and glucose challenge test results.
  • Glucose Challenge Test GDM Screening
  • Fifty gram glucose load was administered orally and blood glucose was measured after one hour.
  • R - 0.3 P ⁇ 0.001 (Spearman correlation).
  • Open circle markers represent GDM cases, filled circle markers represent controls.
  • GDM Gestational diabetes mellitus
  • OGTT oral glucose tolerance test
  • the following table shows exemplary normal glucose levels; levels above these can indicate the presence of GDM.
  • j 1 -hour j Less than 180 mg/dL or 10.0 mmol/L
  • Present treatments generally include a restricted diet and increased exercise and/or the administration of insulin and/or oral hypoglycemic agents, e.g., glyburide or metformin.
  • oral hypoglycemic agents e.g., glyburide or metformin.
  • Follistatin-Like-3 is a structural and functional follistatin homolog which inhibits circulating members of the TGF subfamily of proteins (Tsuchida, K., et al, J Biol Chem, 2000. 275(52): p. 40788-96; Sidis, Y., et al, Endocrinology, 2006. 147(7): p. 3586-97; Schneyer, A., et al, Mol Cell Endocrinol, 2001. 180(1-2): p. 33-8).
  • FSTL3 is expressed by the placenta (Ciarmela, P., et al., J Endocrinol Invest, 2003. 26(7): p. 641-5).
  • FSTL3 and the proteins whose actions it antagonizes may play a major role in glucose homeostasis, as FSTL3 null mice are characterized by pancreatic beta cell hyperplasia and elevated insulin levels, increased glucose tolerance, depletion of liver glycogen stores, and up-regulation of hepatic gluconeogenesis (Mukherjee et al, Pro Natl Acad Sci USA, 2007, 104: 1348-53). Further evidence supporting a role for FSTL3 in glucose homeostasis includes the biologic activities of activin A and myostatin, both of which are antagonized by FSTL3.
  • Activin A promotes differentiation and proliferation of beta-cells along with increased secretion of insulin (Florio, P., et al, J Endocrinol Invest, 2000. 23(4): p. 231-4; Park, M.K., et al., Transplantation, 2007. 83(7): p. 925-30).
  • Myostatin is primarily known for its role as a negative regulator of muscle mass, but its absence has been shown to promote insulin sensitivity and protect against weight gain (Wolf, M., et al, J Clin Endocrinol Metab, 2002. 87(4): p. 1563-8; Gestational diabetes mellitus. Diabetes Care, 2004. 27 Suppl 1 : p. S88-90).
  • FSTL3 is highly expressed by the placentas of infants with intrauterine growth restriction (Okamoto, A., et al, Placenta, 2006. 27(2-3): p. 317-21), and thus may also have a role in the regulation of placental nutrient partitioning.
  • the sequence of the human FSTL3 is available at GenBank Acc. Nos. NM_005860.2 (nucleic acid) and P_005851.1 (protein).
  • the mouse (mus musculus) sequence is available at GenBank Acc. Nos. NM_031380.2 (nucleic acid) and NP_113557.1 (protein).
  • Activin A is a homodimer of the inhibin beta A subunit.
  • the sequence of the human inhibin beta A is available at GenBank Acc. Nos. NM_002192.2 (nucleic acid) and
  • NP_002183.1 protein
  • the mouse (mus musculus) sequence is available at GenBank Acc. Nos. NM_008380.1 (nucleic acid) and NP_032406.1 (protein).
  • NM_005259.2 nucleic acid
  • NP 005250.1 protein
  • GenBank Acc. Nos. NM_010834.2 (nucleic acid) and NP_034964.1 protein
  • the methods described herein can include determining the level of FSTL3 in a sample, i.e., a biological sample, from a subject.
  • the sample can be, e.g., blood, serum, plasma, or urine, but is preferably serum.
  • the sample is obtained from a pregnant woman during the first or second trimester of pregnancy (e.g., at 5 weeks after conception, or in the first trimester (6 to 12 weeks), the second trimester (13 to 27 weeks), or at 8, 10, 12, 14, 16, 18, 20, or 24 weeks after conception, or of gestation); in preferred embodiments, the sample is obtained between 6 and 14 weeks, between 6 and 12 weeks, between 8 and 14 weeks, between 8 and 12 weeks, between 10 and 14 weeks, between 10 and 12 weeks, before 12 weeks, before 14 weeks, or before 15 weeks after conception (or of gestation). References should generally be relevant to the stage of pregnancy.
  • the sample is obtained from a subject who is not fasting.
  • the methods can optionally include determining levels of one or more additional biomarkers for GDM as known in the art and/or described herein, e.g., SHBG, activin, and/or myostatin; a specific cytokine, SHBG, sFLTl, and/or P1GF.
  • the cytokine can be, e.g., an immune/hematopoietin, an interferon, a tumor necrosis factor (TNF)-related molecule or a chemokine. Examples include interleukin (IL)-6, IL-8, IL-lbeta, monocyte chemoattractant protein (MCP)-l or TNF-alpha, or any combination thereof.
  • the methods include determining levels of FSTL3 and SHBG.
  • Methods for determining a level of a biomarker, e.g., FSTL3, in a sample are known in the art, and can include detecting levels of the biomarker, e.g., FSTL3, protein or mRNA using a biomolecule that is specific for the biomarker, e.g., FSTL3.
  • a biomolecule that is specific for the biomarker e.g., FSTL3.
  • an antibody or antigen-binding fragment thereof can be used.
  • Antigen- binding fragments and methods of making them are also known in the art and include an Fab, F(ab')2, Fv, or a single chain Fv (scFv) where the Fvs of an H chain and L chain are linked by a suitable linker (Huston, J.S. el al, Proc. Natl. Acad. Sci. U.S.A., (1998) 85, 5879-5883).
  • Antibodies specific for FSTL3 are known in the art and are commercially available, e.g., from Abeam (Cambridge, MA); Developmental Studies Hybridoma Bank (Iowa City, IA); Novus Biologicals (Littleton, CO); Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); R&D Systems (Minneapolis, MN); and Sigma-Aldrich (St. Louis, MO).
  • Antibodies specific for activin are known in the art and are commercially available, e.g., from Abeam (Cambridge, MA); Thermo Scientific (Rockford, IL.); AbD Serotec (Raleigh, NC); Gen Way Biotech, Inc. (San Diego, CA); Novus Biologicals (Littleton, CO); and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
  • Antibodies specific for myostatin are known in the art and are commercially available, e.g., from Abeam (Cambridge, MA); Alpco Diagnostics (Salem, NH); BioVendor Laboratory Medicine, Inc. (Modrice, Czech Republic);Immundiagnostik (Bensheim, Germany); Novus Biologicals (Littleton, CO); LifeSpan Biosciences (Seattle, WA); and R&D Systems (Minneapolis, MN).
  • Antibodies specific for SHBG are known in the art and are commercially available, e.g., from Abeam (Cambridge, MA); AbD Serotec (Raleigh, NC); Gen Way Biotech, Inc. (San Diego, CA); LifeSpan Biosciences (Seattle, WA); Novus Biologicals (Littleton, CO); R&D Systems (Minneapolis, MN); and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
  • Abeam Cambridge, MA
  • AbD Serotec Radarcomotec
  • Gen Way Biotech, Inc. San Diego, CA
  • LifeSpan Biosciences San Diego, CA
  • Novus Biologicals Liittleton, CO
  • R&D Systems Meapolis, MN
  • Santa Cruz Biotechnology, Inc. Santa Cruz Biotechnology, Inc.
  • the antibodies or antigen-binding fragments thereof are immobilized, e.g., on a substrate, e.g., on a surface (e.g., of an array) or a bead, e.g., latex or polystyrene/latex beads, or magnetic beads. Methods of making such immobilized antibodies are known in the art.
  • the antibodies or antigen-binding fragments thereof can also be modified, e.g., genetically or chemically, e.g., by PEGylation or attachment of a detectable moiety.
  • the detectable moiety can facilitate quantification of the biomarker, e.g., FSTL3, in the sample.
  • the methods can thus include providing a sample, e.g., a sample of serum, and contacting the sample with an antibody under conditions that allow the formation of binding complexes comprising the antibody or antigen-binding fragment thereof and the antigen, i.e., FSTL3, and detecting the formation of those complexes.
  • the methods will generally also include quantitation of the complexes, to determine the quantity of FSTL3 protein present in the original sample.
  • the level of a protein can be determined using methods known in the art, e.g., using quantitative immunoassay methods, including enzyme-linked immunosorbent assays (ELISA). See, e.g., Harlow and Lane, Using Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1998).
  • high throughput methods e.g., protein or gene chips as are known in the art (see, e.g., Ch. 12, Genomics, in Griffiths et al, Eds. Modern genetic Analysis, 1999,W. H. Freeman and Company; Ekins and Chu, Trends in Biotechnology, 1999, 17:217-218; MacBeath and Schreiber, Science 2000, 289(5485): 1760- 1763; Simpson, Proteins and Proteomics: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 2002; Hardiman, Microarrays Methods and Applications: Nuts & Bolts, DNA Press, 2003), can be used to detect the presence and/or level of a biomarker, e.g., FSTL3.
  • a biomarker e.g., FSTL3.
  • levels of free FSTL3, i.e., FSTL3 that is not bound to any other proteins, are determined.
  • levels of bound FSTL3, e.g., levels of FSTL3 bound to a binding partner such as activin and/or myostatin are determined.
  • levels of total FSTL3 are determined, e.g., free plus bound FSTL3.
  • the methods further include calculating a ratio of total FSTL3 to bound FSTL3, or total FSTL3 to free FSTL3, and comparing the ratio with a reference or threshold ratio that is indicative of whether the subject has an increased risk of developing GDM.
  • a number of additional risk factors for the development of GDM are known in the art, and thus the methods described herein can also include the determination of risk based on the presence of an additional risk factor.
  • a factor that increases a subject's risk of developing GDM can include any one or more of: marked obesity; diabetes in a first-degree relative; personal history of glucose intolerance; prior delivery of macrosomic infant; or current glycosuria.
  • GDM GDM-risk ethnicity
  • low-risk ethnicity i.e., other than Hispanic African, Native American, South or East Asian, Pacific Islander, or indigenous Australian
  • no diabetes in first-degree relatives normal pre-pregnancy weight and normal pregnancy weight gain
  • no personal history of abnormal glucose levels no prior poor obstetrical outcomes. See the recommendations of the American Diabetes Assn, Naylor et al, N. Engl. J. Med.
  • the methods include selecting a subject for use of the present methods based on the presence of one or more factors that increase risk for GDM.
  • the methods can also include determining levels of one or more clinically relevant biomarkers of risk for developing GDM. For example, levels of one or more of SHBG, sFLTl, and/or P1GF, interleukin (IL)-6, IL-8, IL-lbeta, monocyte chemoattractant protein (MCP)-l or TNF-alpha can be determined, and the subject's risk can be determined by comparison with a reference levels of the biomarker. See, e.g., U.S. Pat. No. 7,344,892, which is incorporated herein by reference in its entirety.
  • a number of biomarkers, and optionally one or more risk factors, and/or a glucose or insulin test such as homeostasis model assessment-estimated insulin resistance (HOMA-IR), see, e.g., Smirnakis et al, Diabetes Care, 28(5): 1207-1208 (2005), can be used to calculate a composite risk value using methods known in the art.
  • HOMA-IR homeostasis model assessment-estimated insulin resistance
  • the methods described herein include determining a subject's risk of developing GDM based on a comparison of a level of FSTL3 with a reference.
  • the reference FSTL3 level represents a level in a subject having a normal pregnancy; a low level of FSTL3 present in the sample obtained from the pregnant subject (i.e., statistically significantly lower), as compared to the levels present in the reference representing a normal pregnancy, indicates that the pregnant subject has, or is predisposed to having, GDM.
  • a reference level that represents a level of FSTL3 in a normal pregnancy i.e., a level at or above which the subject is considered to have a low or normal risk of developing GDM
  • a reference level that represents a level of FSTL3 in a normal pregnancy can be determined based on a clinical study cohort using methods known in the art.
  • the reference FSTL3 level can represent a level in a subject who has an increased (above normal) risk of developing GDM, and the presence of levels of FSTL3 in the subject that are less than or equal to the level of FSTL3 can indicate an increased risk of developing GDM.
  • an appropriate reference level can be determined based on a clinical study cohort using methods known in the art.
  • the reference FSTL3 level represents a threshold level, and a level in the pregnant subject that is below, or equal to or below, the reference FSTL3 level indicates an increased risk of developing GDM.
  • the reference FSTL3 level is a median level or a cutoff point for a tertile or quartile (e.g., the lowest tertile or quartile), and a level in the pregnant subject that is below, or equal to or below, the reference (e.g., median or cutoff) FSTL3 level indicates an increased risk of developing GDM.
  • Such references can be determined based on a clinical study cohort using methods known in the art.
  • the reference is a threshold level that is set at a percentage of a level in a cohort of subjects who have normal pregnancies, e.g., a level that is 25%, 30%, 40%, 45%, 50%, 55%, or 60% of a level in a normal cohort, e.g., a median level in a normal cohort.
  • the assay is an ELISA
  • the reference level is 4, 6, 8, 10, 12, 14, 16, 18, or 20 ng/ml, or the equivalent thereof using a different assay, and the presence of a level that is at or below that level indicates that the subject has an increased risk of developing GDM.
  • the methods and compositions described herein also provide a means of optimizing the treatment of a subject having such a disorder.
  • the methods can include identifying (and selecting) a subject who is at increased risk of developing GDM based on a method described herein that includes determining levels of FSTL3 in the subject; and administering a treatment (e.g., a treatment that reduces the risk or clinical effects of GDM) to the subject, e.g., as known in the art or described herein, e.g., modifying diet and/or exercise, or administering insulin or an oral hypoglycemic agent such as glyburide.
  • a treatment e.g., a treatment that reduces the risk or clinical effects of GDM
  • the methods can include determining whether that treatment has an effect on levels of FSTL3 in the subject.
  • the treatment can be continued or modified until a level of FSTL3 is attained that indicates a lower risk of developing GDM.
  • the methods can be repeated to monitor changes in FSTL3 levels over time.
  • the methods described herein can be used to identify women at high risk for GDM such that a theranostic approach can be taken to test such individuals to determine the effectiveness of a particular therapeutic intervention (pharmaceutical or non-pharmaceutical) and to alter the intervention to 1) reduce the risk of developing adverse outcomes and 2) enhance the effectiveness of the intervention.
  • the methods described herein can be used to provide a theranostic approach to treating and preventing GDM by integrating diagnostics and therapeutics to improve the real-time treatment of a subject having or at risk for developing GDM. Practically, this means using the present methods to identify which patients are most suited to a particular therapy, and providing feedback on how well a drug is working to optimize treatment regimens.
  • theranostics can flexibly monitor changes in multiple important parameters over time.
  • theranostic multiparameter immunoassays specific for a series of diagnostically relevant molecules e.g., FSTL3 and one or more of the clinically relevant biomarkers described herein, such as MCP- 1, CRP, IL-6, TNF-alpha, sFLTl and/or PIGF
  • a series of diagnostically relevant molecules e.g., FSTL3 and one or more of the clinically relevant biomarkers described herein, such as MCP- 1, CRP, IL-6, TNF-alpha, sFLTl and/or PIGF
  • MCP- 1, CRP, IL-6, TNF-alpha, sFLTl and/or PIGF can be used to follow the progress of a subject undergoing treatment for GDM.
  • the markers provided herein are particularly adaptable for use in diagnosis and treatment because they are available in easily obtained body fluids such as urine, blood or serum.
  • a theranostic method or composition of the invention can provide key information to optimize trial design, monitor efficacy, and enhance drug safety.
  • "trial design” theranostics can be used for patient stratification, determination of patient eligibility (inclusion/exclusion), creation of homogeneous treatment groups, and selection of patient samples that are representative of the general population. Such theranostic tests can therefore provide the means for patient efficacy enrichment, thereby minimizing the number of individuals needed for trial recruitment.
  • "Efficacy” theranostics are useful for monitoring therapy and assessing efficacy criteria.
  • safety theranostics can be used to prevent adverse drug reactions or avoid medication error.
  • MGH Obstetrical Maternal Study is a prospective cohort study of pregnant mothers which has been described previously (Wolf, M., et al, J Clin Endocrinol Metab, 2002. 87(4): p. 1563-8).
  • MOMS MGH Obstetrical Maternal Study
  • the Massachusetts General Hospital obstetrics service provides community -based and high-risk obstetric care for women of varied socioeconomic and ethnic backgrounds from metropolitan Boston and throughout New England.
  • MOMS subjects were recruited women receiving prenatal care at Massachusetts General Hospital and affiliated health centers between 1998 and 2005. Seventy percent of eligible women agreed to enroll in the cohort at their first prenatal visit at around ⁇ 10 weeks of gestation. Blood samples were collected at this time and stored at -80 degrees C for future analysis. Clinical information including age, height, race, last menstrual period, blood pressures and weights measured at prenatal visits, glucose challenge and glucose tolerance test results, mode of delivery, birth weight, and gestational age at delivery was collected from the obstetric electronic medical record. All subjects gave written informed consent.
  • the present study excluded subjects with a history of GDM in a previous pregnancy, preeclampsia (SBP>140 or DBP>100 and dipstick urine protein > 1+), small for gestational age infants ( ⁇ 10 th percentile in weight for gestational age at birth), multiple gestations, and subjects found to have glucose intolerance at less than 20 weeks gestation, as this may have represented pre-gestational diabetes.
  • Standard of care at the MGH obstetric service is to administer a 50 gram, 1 hour, glucose loading test to all pregnant women at 24-28 weeks gestation to screen for GDM. Women whose blood glucose is greater than 140 mg/dL one hour after administration of the glucose challenge undergo subsequent glucose tolerance testing.
  • Glucose tolerance testing consists of the administration of 100 grams of glucose after a 12 hour fast and the measurement of blood glucose levels 0, 1, 2, and 3 hours after glucose administration. GDM cases were defined as those women who had greater than 2 abnormal values on glucose tolerance test in accordance with American Diabetes Association guidelines (Gestational diabetes mellitus. Diabetes Care, 2004. 27 Suppl 1 : p. S88-90). Cases were also required to have an adequate first trimester blood sample available for analysis. Controls were chosen randomly from women who passed the glucose challenge test and/or glucose tolerance test.
  • Optical density at 550 nm was subtracted from optical density at 450 nm and serum concentrations were determined using a standard curve generated by a quadratic plot of the standard sample concentrations versus the measured optical density. Inter-assay coefficient of variation for this assay was approximately 15%.
  • Subject characteristics and levels of FSTL3 in case and control subjects were compared using t-tests, Wilcoxon tests, or chi-squared tests as appropriate. Within the control group, one way analysis of variance was performed to determine whether FSTL3 levels differed in women who had failed the glucose challenge test, but passed the glucose tolerance test. Subjects were divided into tertiles based on FSTL3 levels, and odds ratios for the development of GDM were calculated for each tertile. Logistic regression analysis with appropriate indicator variables was performed to create univariate and multivariate models for the odds of developing GDM. Spearman's correlations between FSTL3 levels, blood glucose levels after 50g and lOOg glucose loads, and other subject characteristics were sought. Logarithmic transformation of FSTL3 levels was performed as appropriate. FSTL3 levels are reported as mean ⁇ standard error of the mean unless otherwise noted. Results
  • the subjects were stratified into quartiles using univariate, multivariate (adjusted for age, BMI, and blood pressure), and OR-univariate model analysis.
  • the results, shown in Fig. 1, demonstrate a clear increase for those subjects in the lowest quartile of FSTL3 levels.
  • Fig. 2 shows the odds ratios for developing GDM based on a first tertile cutpoint of ⁇ 12,000 pg/ml.
  • the OR based on the univariate model was 10.1 (95% CI 5.2-19.6), with a sensitivity of 58% and a PPV of 65%.
  • the OR based on the multivariate model was 12.0 (95% CI 5.8-25.5), with a specificity of 86% and NPV of 83%.
  • Characteristics of the 37 subjects who developed gestational diabetes mellitus and the 127 control subjects are presented in Table 3. Subjects were similar in age, parity, and had similar blood pressures measured at the first prenatal visit. Mean gestational age at the first prenatal visit, the time of blood collection, was 10.9 weeks for all subjects and was similar in both groups. Subjects who developed gestational diabetes mellitus had slightly greater body mass index compared with those who did not, but this difference did not reach statistical significance. There was a greater percentage of Caucasians in the control group compared to the GDM group. Women with GDM delivered earlier in gestation than control women (39.0 ⁇ 0.20 vs. 39.8 ⁇ 0.10 weeks, p ⁇ 0.001), and GDM women gained less weight between the first visit and delivery. Infant birth weight and cesarean section rate did not differ between the groups.
  • P-value reflects: T-test for normally distributed variables: Age, Gestational age, birth Weight. Mann- Whitney- Wilcoxon for non -normally distributed variables: BMI, Blood Pressure, Weight Gain. Chi-squared for categorical variables: Race, Parity, Cesarean-Section. * Significant at the p ⁇ 0.05 level.
  • Glucose challenge test result blood glucose 1 hour after a 50 gram glucose load
  • FSTL3 and non-white race independently predicted glucose challenge test result.
  • FSTL3 levels of FSTL3 were inversely correlated with levels of blood glucose during a 50 gram glucose challenge test. These data are consistent with a role for FSTL3 in GDM pathophysiology. Furthermore, the association between first-trimester FSTL3 levels and subsequent gestational diabetes may allow FSTL3 to be tested as a candidate biomarker for estimation of GDM risk early in pregnancy.
  • the study sample is representative of the pregnant population treated at a large New England hospital, with the exception that no subject had a previous history of GDM. Twenty-three percent of subjects were ethnic/racial minorities. Subjects with and without GDM were similar with the exception of race, gestational age at delivery, and weight gain during pregnancy. Nonwhite race is a known risk factor for GDM (Solomon, C.G, et al, JAMA, 1997. 278(13): p. 1078-83); this likely explains the difference in racial makeup of the case and control group. Women with gestational diabetes mellitus are followed closely for fetal growth and induction of labor or cesarean section is targeted if there is concern for macrosomia (ACOG Practice Bulletin.

Abstract

La présente invention a pour objet des méthodes permettant de déterminer le risque que présente une patiente enceinte de développer une intolérance au glucose et/ou un diabète sucré gestationnel(DSG), basées sur les niveaux du FSTL3, également connu sous le nom de gène associé à la follistatine (FLRG).
PCT/US2010/058708 2009-12-02 2010-12-02 Niveaux de l'analogue 3 de la follistatine (fstl3) dans le diabète gestationnel WO2011068956A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26598709P 2009-12-02 2009-12-02
US61/265,987 2009-12-02

Publications (2)

Publication Number Publication Date
WO2011068956A2 true WO2011068956A2 (fr) 2011-06-09
WO2011068956A3 WO2011068956A3 (fr) 2011-09-29

Family

ID=44115494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/058708 WO2011068956A2 (fr) 2009-12-02 2010-12-02 Niveaux de l'analogue 3 de la follistatine (fstl3) dans le diabète gestationnel

Country Status (1)

Country Link
WO (1) WO2011068956A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103592389A (zh) * 2013-11-15 2014-02-19 湖州市中心医院 一种基于妊娠糖尿病人血清lc/ms代谢组学分析方法
US10444247B2 (en) 2014-09-17 2019-10-15 Wallac Oy Method for determining the risk of preterm birth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074805A1 (en) * 2003-10-03 2005-04-07 Hoffmann-La Roche Inc. Specific markers for diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074805A1 (en) * 2003-10-03 2005-04-07 Hoffmann-La Roche Inc. Specific markers for diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUKHERJEE, A. ET AL.: 'FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.' PNAS vol. 104, no. 4, 2007, pages 1348 - 1353 *
THADHANI, R. ET AL.: 'First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus.' AUS. J. DERM. vol. 49, no. ISS.2, March 2010, pages 67 - 74 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103592389A (zh) * 2013-11-15 2014-02-19 湖州市中心医院 一种基于妊娠糖尿病人血清lc/ms代谢组学分析方法
US10444247B2 (en) 2014-09-17 2019-10-15 Wallac Oy Method for determining the risk of preterm birth
US11255861B2 (en) 2014-09-17 2022-02-22 Wallac Oy Method for determining the risk of preterm birth

Also Published As

Publication number Publication date
WO2011068956A3 (fr) 2011-09-29

Similar Documents

Publication Publication Date Title
Rawal et al. A longitudinal study of iron status during pregnancy and the risk of gestational diabetes: findings from a prospective, multiracial cohort
Barton et al. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study
AU2010240781B2 (en) Methods for determining maternal health risks
US20230341414A1 (en) Systems and methods to identify and treat subjects at risk for obstetrical complications
US11333672B2 (en) Preeclampsia biomarkers and related systems and methods
US20110183434A1 (en) Diagnostic methods and kits using fibroblast growth factor-23
US20190128895A1 (en) Methods and compositions for prognosing preterm birth
US20140348818A1 (en) Biomarkers of kawasaki disease
JP2019522782A (ja) 子癇前症の評価を提供するための方法及び組成物
JP2013503329A (ja) 有害事象の予後診断のためのプロカルシトニン
Zeron et al. Hyperleptinemia as a prognostic factor for preeclampsia: a cohort study
Tarca et al. Human plasma proteome during normal pregnancy
Güngör et al. Impact of body mass index and vitamin D on serum AMH levels and antral follicle count in PCOS
US20190079097A1 (en) Preeclampsia biomarkers and related systems and methods
Kirici et al. Determination of maternal serum pro-inflammatory cytokine changes in intrauterine growth restriction
US8097424B2 (en) Method for predicting the outcome of a critically ill patient
Eleje et al. Diagnostic value of Chorioquick for detecting chorioamnionitis in women with premature rupture of membranes
WO2011068956A2 (fr) Niveaux de l'analogue 3 de la follistatine (fstl3) dans le diabète gestationnel
Spinillo et al. Placental pathologic features in thyroid autoimmunity
CA2794021A1 (fr) Hbf et a1m a titre de marqueurs precoces de preeclampsie
JP2017516119A (ja) 初期胎盤インスリン様ペプチド（プロ（ｐｒｏ）−ＥＰＩＬ）
US20140057295A1 (en) Anti-mullerian hormone changes in pregnancy and prediction of adverse pregnancy outcomes and gender
Simpson et al. Peri‐implantation cytokine profile differs between singleton and twin IVF pregnancies
US9068990B2 (en) Methods of predicting and decreasing the risk of pregnancy loss
CN116547536A (zh) 用于预测患有covid-19的患者的疾病严重度的gdf-15

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10835114

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 14/09/2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10835114

Country of ref document: EP

Kind code of ref document: A2